LITTLE ROCK, Ark.— An execution drug obtained by the Arkansas prison system earlier this month appears to have been made by a subsidiary of Pfizer, even though the pharmaceutical giant has said it doesn't want its drugs to be used in executions. It matches labels submitted to the National Institutes of Health by Hospira, Inc., which Pfizer bought last year. » Read More
Despite the ongoing recession, generic drug makers like Teva Pharmaceutical and Watson Pharmaceutical have been outperforming in the broader market. CEOs William Marth and Paul Bisaro both expect to see further growth.
Is there a pipeline from the C-suite of McDonald's to the ivory towers of biopharma? At least one "Pharma's Market" reader from overseas thinks so.
The "Amgen Tour of California" is getting a lot more publicity than usual because superstar cyclists Lance Armstrong and Floyd Landis are trying to make comebacks in the race.
Yes, McDonald's has done away with "Super-Size" menu items, but I can still use the American lexicon for, hopefully, an attention-grabbing blog headline.
CardioNet caught my eye and attention when I got a research note from Rick Wise at Leerink Swann about BEAT beating the Street.
Attendance at the 4th Annual Stem Cell Summit is up, by about 50 percent, no less, over last year. All day long privately-held and publicly-traded companies are presenting to around 250 investors.
Correction: A story that appeared on Feb. 13 erroneously stated that CV Therapeutics agreed to a $1 billion takeover bid by pharmaceutical firm Astellas Pharma. There has been no agreement.
Friday the 13th. My lucky day for reaching into the Pharma's Market mailbag. Time for your Emails.
I thought the dust had pretty much settled on the Pfizer-Wyeth story. Then this morning two analysts coincidentally put out research notes on it.
What's $23 between friends, er, sparring business partners? The question brings back memories of my grandfather who was of the generation that would hold a grudge for years against a distant relative who still owed him a small amount of money.
I've been trying for years to get an interview with Genentech CEO Art Levinson. As far as I know, he's never done a TV chat. Every time I've asked the answer has come back no. I've gotten pretty good access to other execs, but never the top dog.
Shares of Swiss drugmaker Roche are trading significantly lower overseas and in over-the-counter activity here in the States after the company reported earnings.
Right around the closing bell today an FDA advisory committee voted unanimously in favor of recommending approval of Eli Lilly's bloodthinner called Effient.
Before Gardasil came to market two to three years ago, some analysts were saying it would become the biggest-selling vaccine in history. But hope and reality have turned out to be two different things.
If so, that could mean big bucks for this pharmacy-benefits manager.
Diabetes drugmaker Amylin Pharmaceuticals is headquartered in San Diego. Like a lot of companies, though, it's incorporated in Delaware. But, if a couple of major shareholders get their way, AMLN could reincorporate in an unlikely state.
So, what do you do at the end of a week where your company's stock was the worst performer in the Dow and you've got some bad news that could make the shares go down even more? You employ one of the oldest PR tricks in the book.
Genentech shares dropped three percent today or $2.85 to $81.24 after Roche showed some chutzpah and lowered its bid for DNA.
That’s the possible result after today's shocking DNA test.
Pfizer is quitting the ad agency that tried to tell smokers it's their time to quit.